5:02 AM
 | 
Mar 25, 2019
 |  BC Extra  |  Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

Editor's Note: This article was updated on Mar 25, 2019 at 12:32 PM PDT

Backed by new investor Lightchain, Arch Oncology raised $50 million in a series B round to enable the company to advance its anti-CD47 mAb, AO-176, which is in a Phase I trial...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >